Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Biologics better solo than with methotrexate in psoriatic arthritis
Key clinical point: Methotrexate does not enhance ustekinumab or TNFi effects in the treatment of psoriatic arthritis.
Major finding: For all measures of psoriatic arthritis disease activity assessed at 6 months, there was no additional benefit of using methotrexate with either ustekinumab or a TNFi.
Study details: The PsABio study (NCT02627768), an ongoing, prospective, observational cohort study of almost 1,000 patients with psoriatic arthritis.
Disclosures: The study was funded by Janssen. Dr. Siebert has acted as a consultant to and received research funding from Janssen, UCB, Pfizer, Boehringer Ingelheim, Novartis, and Celgene. He has also acted as a consultant for AbbVie and received research support from Bristol-Myers Squibb.
Siebert S et al. Rheumatology. 2020;59(Suppl 2). doi: 10.1093/rheumatology/keaa110.023, Abstract O24.